News Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.
R&D Sponsored Type 1 diabetes: The importance of early screening and diagn... This article was organised, funded, and reviewed by Sanofi.
News FDA fast-tracks Sanofi's experimental chlamydia vaccine Sanofi is preparing to start human testing of its chlamydia vaccine, now fast-tracked by the FDA, that it hopes will be the first to reach the market.
News FDA starts review of Sanofi's MS hope tolebrutinib Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis.
News Sanofi signs $1.9bn deal to buy Dren Bio autoimmune drug Sanofi buys a drug from Dren Bio to claim a stake in the emerging field of deep B-cell depletion for autoimmune diseases.
News Can Dupixent plug treatment gap in bullous pemphigoid? The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
